Previous 10 | Next 10 |
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administrat...
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will present new preclinical data demonstrating that ST...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have never really managed to recreate the success they had in 2020 amid the Covid-19 outbreak. For a second year in running, the sector is caught in a rut, underperforming the beaten-down broader market. Th...
Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...
WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage sel...
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune diseases in a manner superior to kinase inhibitors -Findings support furth...
Kymera Therapeutics, Inc. (KYMR) Q1 2022 Results Conference Call May 03, 2022 08:00 AM ET Company Participants Nello Mainolfi - Founder and Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Brad ...
Shares of Kymera Therapeutics (NASDAQ: KYMR) , a clinical-stage biopharmaceutical company, are tumbling in response to its latest quarterly update. Kymera said it is updating a clinical trial testing the company's lead candidate, which will cause the study to last longer than ex...
Gainers: Sonoma Pharmaceuticals (SNOA) +29%. Blue Water Vaccines (BWV) +32%. XORTX Therapeutics (XRTX) +27%. Eqonex (EQOS) +21%. TETRA Technologies (TTI) +20%. Enovix (ENVX) +18%. JAKKS Pacific (JAKK) +18%. Blue Apron Holdings (APRN) +17%. Borr Drilling (BORR) +16%. Western Digital Corp...
The shares of Kymera Therapeutics (NASDAQ:KYMR) have reached a 52-week low after the clinical-stage biotech reported a sharp revenue miss and provided a clinical update that could potentially delay its Phase 1 program for KT-474 targeted at immunology-inflammation diseases. KT-474 is currentl...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...